ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

1,4100

22-ноября-24 16:44:58

15 мин. задержка

Акции

+0,1200

+9,30%

Сегодняшний диапазон

1,2700 - 1,4400

ISIN

N/A

Источник

NASDAQ

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

13 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire
ALX Oncology Announces November Investor Conference Participation

01 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

10 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Pricing of Public Offering

05 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Proposed Public Offering

04 окт 2023 16:10:18 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

03 окт 2023 06:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

02 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Realigns Executive Leadership Team

06 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces September Investor Conference Participation

31 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

10 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

26 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

11 май 2023 16:01:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

09 май 2023 07:00:02 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

25 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

13 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

09 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

16 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

05 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12 дек 2022 10:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.